Figure 2
Figure 2. CD56+ cell migration occurs independently of CXCR3. Radiolabeled MACS-isolated CD56+ cells were pretreated with either pertussis toxin (PTX; top) or an anti-CXCR3 (20 μg/mL) or isotype control mAb (bottom) preceding chemotaxis in 96-well chemotaxis assays to supernatants from poly(I:C) [p(I:C)]– or medium (med)–stimulated CBMCs for 2 hours. Poly(I:C) was added to medium alone to control for potential chemotactic/chemokinetic effects of the poly(I:C). The chemokine CXCL10 (200 ng/mL) was used as a positive control for anti-CXCR3 mAb inhibition of chemotaxis. Mean migration to poly(I:C)-CBMC supernatants: top, 12.9%; bottom, 8.2%. Graphs represent the mean (± SEM) of the fold increase in chemotaxis over medium of 3 to 8 separate experiments. Dashed line indicates baseline chemotaxis to medium only. *P < .05, **P < .01, compared with CBMC medium; †P < .05, ††P < .01, compared with no treatment.

CD56+ cell migration occurs independently of CXCR3. Radiolabeled MACS-isolated CD56+ cells were pretreated with either pertussis toxin (PTX; top) or an anti-CXCR3 (20 μg/mL) or isotype control mAb (bottom) preceding chemotaxis in 96-well chemotaxis assays to supernatants from poly(I:C) [p(I:C)]– or medium (med)–stimulated CBMCs for 2 hours. Poly(I:C) was added to medium alone to control for potential chemotactic/chemokinetic effects of the poly(I:C). The chemokine CXCL10 (200 ng/mL) was used as a positive control for anti-CXCR3 mAb inhibition of chemotaxis. Mean migration to poly(I:C)-CBMC supernatants: top, 12.9%; bottom, 8.2%. Graphs represent the mean (± SEM) of the fold increase in chemotaxis over medium of 3 to 8 separate experiments. Dashed line indicates baseline chemotaxis to medium only. *P < .05, **P < .01, compared with CBMC medium; †P < .05, ††P < .01, compared with no treatment.

Close Modal

or Create an Account

Close Modal
Close Modal